Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PRQR, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sepofarsen | Leber Congenital Amaurosis 10 | Phase 2/3 · NCT03913143 | Active not recruiting |
| QR-010 | Cystic Fibrosis | Phase 1/2 · NCT02532764 | Completed |
| QR-1123 | Autosomal Dominant Retinitis Pigmentosa | Phase 1/2 · NCT04123626 | Active not recruiting |
| QR-421a | Retinitis Pigmentosa | Phase 1/2 · NCT03780257 | Completed |
| QR-504a | Fuchs Endothelial Corneal Dystrophy | Phase 1 · NCT05052554 | Withdrawn |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PRQR holds $117.1M in cash and short-term investments and burns about $12.3M/quarter from operations, an estimated runway of 28.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRQR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| ELI LILLY & Co | 5%+ holder (13G) | 21,995,880 | 20.88% | 2026-06-26 |
| Van Herk Investments B.V. | 5%+ holder (13D) | 15,384,250 | 14.60% | 2026-07-27 |
| Adage Capital Partners GP L.L.C. | Institution (13F) | 9,015,897 | 8.56% | 2026-06-30 |
| Aberdeen Group plc | Institution (13G, 5%+) | 8,932,507 | 8.48% | 2026-06-30 |
| Affinity Asset Advisors, Llc | Institution (13F) | 5,543,936 | 5.26% | 2026-06-30 |
| PATRICK JOHAN HENDRIK KROL | Institution (13G, 5%+) | 5,528,862 | 5.25% | 2026-07-15 |
| Privium Fund Management B.V. | Institution (13F) | 5,520,024 | 5.24% | 2026-06-30 |
| Ikarian Capital, LLC | Institution (13F) | 3,425,930 | 3.25% | 2026-06-30 |
| Woodline Partners LP | Institution (13F) | 3,277,143 | 3.11% | 2026-06-30 |
| Heights Capital Management, Inc | Institution (13F) | 2,762,430 | 2.62% | 2026-06-30 |
| Morgan Stanley | Institution (13F) | 1,767,215 | 1.68% | 2026-06-30 |
| Sphera Funds Management Ltd. | Institution (13F) | 1,757,458 | 1.67% | 2026-06-30 |
Share count 105,361,064 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-07-31 filed 2026-08-03 |
de Boer Daniel Anton |
Purchase (P) | 200,000 | $1.77 | 500,000 |
| 2026-07-17 filed 2026-07-21 |
Filius Bart |
Purchase (P) | 150,000 | $1.72 | 300,000 |
| 2026-07-09 filed 2026-07-13 |
de Boer Daniel Anton |
Purchase (P) | 150,000 | $1.74 | 300,000 |
| 2026-07-07 filed 2026-07-08 |
de Boer Daniel Anton |
Purchase (P) | 150,000 | $1.59 | 150,000 |
| 2026-06-02 filed 2026-06-03 |
Hinsch Gylvin Lykke |
Option award (A) | 14,495 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRQR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →